Targeted therapies for CLL: Practical issues with the changing treatment paradigm

Blood Reviews
Nitin Jain, Susan M O'Brien

Abstract

Chemoimmunotherapy (CIT) such as FCR (fludarabine, cyclophosphamide, rituximab) has been the standard first-line therapy for younger patients with CLL. In the last few years, several novel targeted therapies have been developed for patients with CLL. These include B-cell receptor (BCR) inhibitors such as Bruton tyrosine kinase (BTK) inhibitors, PI3 kinase inhibitors, and Syk inhibitors, novel anti-CD20 monoclonal antibodies such as ofatumumab and obinutuzumab, and Bcl-2 antagonists such as venetoclax (ABT-199). Strategies targeting the immune system such as lenalidomide, chimeric antigen receptor (CAR) T cells, and more recently, checkpoint inhibitors, are in clinical development. Ibrutinib and idelalisib are already approved for patients with relapsed and refractory CLL. Ibrutinib is also approved for first-line treatment of CLL patients with del(17p). Several ongoing phase III clinical trials with novel therapies will further define the role of targeted agents in CLL.

References

Jul 20, 2002·Science·Klaus OkkenhaugBart Vanhaesebroeck
Oct 11, 2003·Annals of Hematology·Patrick D ThorntonDaniel Catovsky
Feb 14, 2004·Blood·Freda K Stevenson, Federico Caligaris-Cappio
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Greg A LazarBassil I Dahiyat
Sep 2, 2006·The Journal of Pharmacology and Experimental Therapeutics·Sylvia BraselmannEsteban S Masuda
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
Dec 13, 2006·ChemMedChem·Zhengying PanJames T Palmer
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John C ByrdSarah Harris
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas S LinJohn C Byrd
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaUNKNOWN Hx-CD20-406 Study Investigators
Jul 8, 2010·The Journal of Pharmacology and Experimental Therapeutics·Ronald HerbstAnthony J Coyle
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine I ChenSuzanne Trudel
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Jan 10, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andres Forero-TorresKristen N Ganjoo

❮ Previous
Next ❯

Citations

Jun 29, 2016·Expert Review of Hematology·Nitin Jain, Michael J Keating
Nov 5, 2016·Blood·Nitin Jain, Susan O'Brien
Sep 9, 2017·Nature Medicine·Anthony Letai
Dec 7, 2018·Hematology·Nitin Jain
Nov 26, 2019·The Cancer Journal·Nitin Jain, Susan OʼBrien
Oct 9, 2019·Current Opinion in Oncology·Luana SchiattoneLydia Scarfò
Dec 18, 2019·Current Medical Science·Xin YangJian-Feng Zhou
Jun 14, 2016·British Journal of Haematology·David J M Routledge, Adrian J C Bloor
Feb 2, 2018·Translational Behavioral Medicine·Gabrielle B RocqueMonika M Safford
Jun 6, 2018·Cancer Metastasis Reviews·Typhaine AnquetilJulien Viaud
Dec 4, 2016·Hematology·Nitin Jain, Susan O'Brien
Nov 12, 2017·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Lonneke van de Poll-FranseUNKNOWN EORTC Quality of Life Group
Sep 26, 2017·Clinical Journal of Oncology Nursing·Heather Brumbaugh ParadisDiane Llerandi
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Erel JoffeAnas Younes
Jun 8, 2017·Clinical Case Reports·Amara G NandikollaMurali Janakiram
Jul 25, 2018·Journal of Investigative Medicine High Impact Case Reports·Jason HewVinay Minocha
Oct 9, 2019·Cancer Biomarkers : Section a of Disease Markers·Zhenhai JingQing Hong
Sep 15, 2020·Journal of Thrombosis and Haemostasis : JTH·Jennifer SeriesBernard Payrastre
Feb 26, 2021·Journal of Hematology & Oncology·Timothy L ChenErin Hertlein
Jan 17, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Iris de WeerdtHans J van der Vliet
Jul 25, 2021·Cancers·Dimitra MavridouMichalis Aivaliotis
Aug 21, 2021·Stem Cell Research & Therapy·Faroogh MarofiMostafa Jarahian
Mar 19, 2021·Blood·Laura BeckmannLukas P Frenzel
Aug 31, 2021·Journal of Patient Experience·Elissa C KranzlerAlexandra K Zaleta
Oct 19, 2021·Frontiers in Oncology·Mahnaz RezaeiMazdak Ganjalikhani-Hakemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

American Journal of Hematology
Kanti R Rai, Preetesh Jain
Expert Opinion on Biological Therapy
Preetesh Jain, Susan M O'Brien
Clinical Lymphoma, Myeloma & Leukemia
Carolyn OwenLaurie Sehn
© 2022 Meta ULC. All rights reserved